P0592Tasty&Healthy whole food diet induces distinct metabolomics signatures in Crohn’s disease: results from the TASTI-MM and TASTI-E randomized controlled trials

Abstract Background Tasty 8 in TASTI-MM and by 50% decrease in calprotectin in TASTI-E. Univariate testing with multiple comparisons correction (FDR0.25) were applied to each week, measured both in absolute level and in relative to baseline level. Principal component analysis (PCA) was applied for each metabolomics dataset to identify total signature shift or trends in metabolic patterns. Finally, metabolite set enrichment analysis (MESA) was applied to identify biological pathways associated with the diets using MetaboAnalyst v6.0, reporting pathway-level enrichment strength (Q statistic 10) and significance (FDR 0.05). Results Overall 121 children were enrolled in both RCTs with a total of 227 serum samples and 312 fecal samples collected over the RCTs’ duration with no observed metabolic differences at baseline. 140 serum and 63 fecal metabolites (in both weeks 4 and 8) consistently differed between T 10, FDR 0.05 at both weeks 4 and 8) of butyrate, histidine and tryptophan metabolism pathways in the T&H group in comparison to EEN. Conclusion The T&H diet promoted a distinct systemic metabolic signature which differed from those treated with EEN or continuing their habitual diet. The consistent and robust enrichment of butyrate, histidine and tryptophan metabolism pathways points to restoration of host–microbial amino acid and short-chain fatty acid networks that are implicated in intestinal homeostasis and immune regulation. Conflict of interest: Mr. Azulay, Asaf: No conflict of interest Plotkin, Luba: No conflict of interest Aharoni-Frutkoff, Yonat: No conflict of interest Livovsky, Jessica: No conflict of interest Focht, Gili: Other: Received in the past 3 years consultation fee from Lilly Lev Zion, Raffi: No conflict of interest Ledder, Oren: No conflict of interest Assa, Amit: No conflict of interest Yogev, Dotan: No conflict of interest Orlansky Meyer, Esther: No conflict of interest Broide, Efrat: No conflict of interest Kierkuś, Jarosław: Grant: Nestle Other: Nutricia, Abbvie, Nestle Kang, Ben: Other: For the past 3 years, Ben Kang has served as a speaker or consultant for Celltrion, Janssen, Eisai, Abbvie, Takeda, Yuhan, Yungjin, JW Pharmaceutical, and Samsung Bioepis and has received research funding from Celltrion. Weiss, Batia: No conflict of interest Aloi, Marina: Personal Fees: AbbVie Pfizer Dicofarm Slae, Mordechai: No conflict of interest Yerushalmy-Feler, Anat: No conflict of interest Wine, Eytan: Personal Fees: Janssen, AbbVie, Nestle Health Sciences, Mead Johnson Nutrition, Pfizer, BioJamp Turner, Dan: Consultation fee: Janssen, Pfizer, Ferring, Abbvie, Takeda, Prometheus Biosciences, Lilly, SorrisoPharma, Boehringer Ingelheim, Galapagos, BMS, AlfaSigma, Merck, Gentech Research support: Janssen, Abbvie, Takeda, Pfizer Royalties: Shaare Zedek Medical Center, Hospital for Sick Children